Literature DB >> 2891370

Effects of antacids and food on absorption of famotidine.

J H Lin1, A N Chremos, S M Kanovsky, S Schwartz, K C Yeh, J Kann.   

Abstract

The effect of a high potency antacid and food on the bioavailability of famotidine was studied in 17 healthy volunteers in an open randomized three-way cross-over trial. After an overnight fast, famotidine was administered to each subject as follows: 40 mg famotidine orally alone; 40 mg orally with antacid; and 40 mg orally with a standard breakfast. Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05). However, there was only a minimal effect of food on these parameters; the Cmax and [AUC] were 81.6 +/- 29.6 ng ml-1 and 434.8 +/- 145.9 ng ml-1 h, respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891370      PMCID: PMC1386320          DOI: 10.1111/j.1365-2125.1987.tb03211.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Novel method for bioavailability assessment.

Authors:  K C Kwan; A E Till
Journal:  J Pharm Sci       Date:  1973-09       Impact factor: 3.534

2.  Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine.

Authors:  W C Vincek; M L Constanzer; G A Hessey; W F Bayne
Journal:  J Chromatogr       Date:  1985-03-22

3.  High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.

Authors:  G W Mihaly; A T Marino; L K Webster; D B Jones; W J Louis; R A Smallwood
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

4.  Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.

Authors:  R G Pendleton; M L Torchiana; C Chung; P Cook; S Wiese; B V Clineschmidt
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-11

5.  Urinary excretion kinetics of famotidine in rats.

Authors:  J H Lin; L E Los; E H Ulm; D E Duggan
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

6.  Impaired cimetidine absorption due to antacids and metoclopramide.

Authors:  R Gugler; M Brand; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  6 in total
  16 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.

Authors:  G Kraus; D R Krishna; D Chmelarsch; M Schmid; U Klotz
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 5.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

6.  Does smoking influence the pharmacokinetics and pharmacodynamics of the H2-receptor antagonist famotidine?

Authors:  L C Baak; S Ganesh; J B Jansen; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

Review 7.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

9.  Pharmacokinetics of famotidine in patients with cirrhosis and ascites.

Authors:  G Vinçon; C Baldit; P Couzigou; F Demotes-Mainard; L Elouaer-Blanc; B Bannwarth; B Begaud
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.

Authors:  J H Lin; A N Chremos; K C Yeh; J Antonello; G A Hessey
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.